Life Sciences Partner News Today

Search HighlightsRecent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.This quarter’s successful placements include:FunctionFocus areaLocationCEOTherapeutic devicesAustriaChief Business Officer...

Operator: Ladies and gentlemen, thanks for standing by. At this time, I would like to welcome everyone to the IQVIA Second Quarter 2023 Earnings Conference Call.

Further recognition as winner of the Microsoft Japan Global System Integrator (GSI) award and Government award categories, and selection as finalist in GSI award, SAP on Azure award, Defense & Intelligence award categories of the Microsoft ...

/PRNewswire/ -- Volpara Health (ASX: VHT), a global leader in software for the early detection of breast cancer, today announced it has won the Healthcare &...

COLUMBUS, Ohio--(BUSINESS WIRE)--Invirsa Inc., a privately held, clinical-stage pharmaceutical company focused on developing an innovative topically administered eyedrop formulation INV-102 for ocular conditions associated with DNA damage, announced the closing of a $7.7 million Series B financing completed in April...

The new Medicare price negotiation program, inflation-based rebates, and other changes to how Medicare ..

The reported cancer incidence in India this year is estimated to be 19 to 20 lakh, whereas real incidence is 1.5 to 3 times higher than the reported cases, according to a study by FICCI and EY titled

Real cancer incidence level in India is estimated to be 1.5 to three times higher than reported incidence as 51 per cent patients take more than a week to conclude diagnosis while 46 per cent take second opinion due to lack of confidence in initial diagnosis and suggested treatment, a report showed on Tuesday.

New Delhi, Oct 11 (IANS) Real cancer incidence level in India is estimated to be 1.5 to three times higher than reported incidence as 51 per cent patients

Real cancer incidence level in India is estimated to be 1.5 to three times higher than reported incidence as 51 per cent patients take more than a week to conclude diagnosis while 46 per cent take second opinion due to lack of confidence in initial diagnosis and suggested treatment, a report showed